Quarterly report pursuant to Section 13 or 15(d)

Stockholders??? Equity

v3.24.3
Stockholders’ Equity
9 Months Ended
Sep. 30, 2024
Stockholders’ Equity [Abstracf]  
Stockholders’ Equity

Note 7. Stockholders’ Equity

 

Authorized Shares

 

The Company has 45,000,000 Common shares and 900,000 Series A convertible preferred shares authorized with a par value of $0.001 per share.

 

On October 6, 2023, following stockholder approval at the Company’s annual meeting, the Company amended its certificate of incorporation to implement a 1 for 15 reverse split of its common stock. The effect of the reverse stock split was to combine every 15 shares of outstanding common stock into one share of common stock. The reverse stock split was effective at the opening of the trading day on October 11, 2023. The effects of the reverse stock split have been reflected in this quarterly report on form 10/Q for all periods presented.

 

Common Stock

 

Issuance of Shares for Vested Restricted Stock Units

 

March 27, 2024, the Company issued 1,667 shares of common stock to a holder of fully vested restricted stock units.

 

Issuance of Shares as Settlement of Accounts Payable

 

Between February 6, 2024 and July 11, 2024, the Company issued an aggregate 130,039 shares of common stock in full settlement of $239,815 of accounts payable. The shares had fair values ranging from $1.20 to $2.65 per share.

 

Issuance of Shares for Legal Settlements

 

On May 30, 2024, the Company issued 37,500 shares of common stock valued at $67,200 or $1.79 per share to fulfill its obligation under a previous legal settlement. See Note 6. Commitments and Contingencies for further information.

 

On July 15, 2024, the Company issued 38,052 shares of common stock valued at $53,653 or $1.41 per share to settle a potential legal claim.

 

On July 18, 2024, the Company issued 159,776 shares of common stock valued at $218,094 or $1.36 per share as partial fulfillment its obligation under a previous legal settlement. See Note 6. Commitments and Contingencies for further information.

 

Warrants issued in conjunction with loans payable

 

On July 15, 2024, the Company issued warrants to purchase an aggregate 4,887,118 shares of the Company’s common stock at exercise prices ranging from $1.43 to $1.692 per share in conjunction with a convertible note issuance, see Note 4. Loans Payable. The warrants were valued at $6,163,572  using the Black-Scholes pricing model.  The Company has recognized $973,200 of this value as a discount to the associated notes.

 

The Company has classified the warrants as having Level 2 inputs, and has used the Black-Scholes option-pricing model to value the warrants.

 

The fair values at the commitment date for the warrants were based upon the following management assumptions as of the date of issuance:

 

    Issuance
date
 
Risk-free interest rate     1.93 %
Expected dividend yield    
-
%
Expected volatility     144 %
Term      5 years  
Fair value of common stock   $ 1.41  

 

Stock Incentive Plan

 

The number of shares of the Company’s common stock that are issuable pursuant to warrant and stock option grants with time-based vesting as of and for the nine months ended September 30, 2024 were:

 

    Warrant Grants     Stock Option Grants     Restricted
Stock
Units
 
    Number of
shares
subject to
warrants
    Weighted-
average
exercise
price per
share
    Number of
shares
subject to
options
    Weighted-
average
exercise
price per
share
    Number of
shares
subject to
restricted
stock units
 
Balance at December 31, 2023     11,394     $ 58.72       3,333     $ 39.60       165,663  
Granted     4,887,118       1.53      
-
     
-
      123,690  
Exercised    
-
     
-
     
-
     
-
      (125,357 )
Cancelled/Expired     (2,293 )     53.64      
-
     
-
      (41,722 )
Balance at September 30, 2024     4,896,219     $ 1.64       3,333     $ 39.60       122,274  
Exercisable at September 30, 2024     4,896,219     $ 1.64       3,333     $ 39.60       122,274  

 

The number of shares of the Company’s common stock that are issuable pursuant to warrant and stock option grants with time-based vesting as of and for the nine months ended September 30, 2023 were:

 

    Warrant Grants     Stock Option Grants     Restricted
Stock
Units
 
    Number of
shares
subject to
warrants
    Weighted-
average
exercise
price per
share
    Number of
shares
subject to
options
    Weighted-
average
exercise
price per
share
    Number of
shares
subject to
restricted
stock units
 
Balance at December 31, 2022     104,515     $ 20.25       7,889     $ 48.75       160,650  
Granted    
-
     
-
     
-
     
-
      58,105  
Exercised     (54,872 )     9.75      
-
     
-
      (47,706 )
Cancelled/Expired     (4,812 )     120.75       (1,222 )     98.55       (4,610 )
Balance at September 30, 2023     44,831     $ 22.20       6,667     $ 39.60       166,439  
Exercisable at September 30, 2023     44,831     $ 22.20       6,667     $ 39.60       162,606  

 

The Company’s outstanding warrants and options at September 30, 2024 are as follows:

 

Warrants Outstanding     Warrants Exercisable  
Exercise Price
Range
    Number
Outstanding
      Weighted Average
Remaining
Contractual Life
(in years)
      Weighted
Average
Exercise Price
    Number
Exercisable
    Weighted
Average
Exercise Price
      Intrinsic
Value
 
$1.43 - $60.00     4,896,219       4.79     $ 1.64     4,896,219   $ 1.64      
        -
 

 

Options Outstanding     Options Exercisable  
Exercise Price
Range
  Number
Outstanding
    Weighted Average
Remaining
Contractual Life
(in years)
    Weighted
Average
Exercise Price
    Number
Exercisable
  Weighted
Average
Exercise Price
    Intrinsic
Value
 
$39.60     3,333       0.16     $ 39.60     3,333   $ 39.60      
   -
 

 

As of September 30, 2024 and December 31, 2023, there was no unrecognized expense for unvested stock options and restricted stock awards.

 

Stock-based compensation expense for three and nine months ended September 30, 2024 and 2023 is as follows:

 

    For the three months ended     For the nine months ended  
    September 30,     September 30,  
    2024     2023     2024     2023  
Stock-based compensation expense   $
      -
    $ 40,547     $
        -
    $ 336,293